Literature DB >> 3689982

Prognostic factors for recurrence and survival in human breast cancer.

W L McGuire1.   

Abstract

Since only about half of primary breast cancer patients are cured by local treatment, factors which can predict which patients are likely to recur and should thus receive preventive treatment are needed. Here, work on such prognostic factors which has been going on in San Antonio for many years will be reviewed. The significance of the number of involved axillary nodes and of steroid receptors is already well known, while the value of tumor proliferative rate and ploidy has been appreciated more recently, and the significance of amplification of the oncogene HER-2/neu is just now emerging.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689982     DOI: 10.1007/bf01806129

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Impact of flow cytometry on predicting recurrence and survival in breast cancer patients.

Authors:  W l McGuire; J S Meyer; B Barlogie; T E Kute
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

2.  Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients.

Authors:  W L McGuire; L G Dressler
Journal:  J Natl Cancer Inst       Date:  1985-09       Impact factor: 13.506

3.  The long-term prognostic significance of the thymidine labelling index in breast cancer.

Authors:  M Tubiana; M H Pejovic; N Chavaudra; G Contesso; E P Malaise
Journal:  Int J Cancer       Date:  1984-04-15       Impact factor: 7.396

4.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.

Authors:  W A Knight; R B Livingston; E J Gregory; W L McGuire
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  Progesterone receptors as a prognostic factor in Stage II breast cancer.

Authors:  G M Clark; W L McGuire; C A Hubay; O H Pearson; J S Marshall
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

7.  Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma.

Authors:  J S Meyer
Journal:  NCI Monogr       Date:  1986

8.  Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; G Di Fronzo; A Morabito; P Valagussa; G Bonadonna
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

  8 in total
  43 in total

1.  Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes.

Authors:  Jennifer Pittman; Erich Huang; Holly Dressman; Cheng-Fang Horng; Skye H Cheng; Mei-Hua Tsou; Chii-Ming Chen; Andrea Bild; Edwin S Iversen; Andrew T Huang; Joseph R Nevins; Mike West
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-19       Impact factor: 11.205

2.  Has adjuvant treatment of breast cancer had an unfair trial?

Authors:  I Mittra
Journal:  BMJ       Date:  1990-12-08

3.  An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activity in vitro: experience on 136 primary cancers and on 116 recurrences.

Authors:  W Zoli; A Volpi; C Bonaguri; A Riccobon; S Savini; R Brizio; A Saragoni; L Medri; G A Marra; D Amadori
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

Review 4.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

5.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

6.  Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases.

Authors:  J D Jacquemier; J Hassoun; M Torrente; P M Martin
Journal:  Breast Cancer Res Treat       Date:  1990-02       Impact factor: 4.872

7.  Proliferation of normal breast epithelial cells as shown by in vivo labeling with bromodeoxyuridine.

Authors:  K Christov; K L Chew; B M Ljung; F M Waldman; L A Duarte; W H Goodson; H S Smith; B H Mayall
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

Review 8.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

9.  Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer.

Authors:  P Shrestha; K Yamada; T Wada; S Maeda; M Watatani; M Yasutomi; H Takagi; M Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 10.  Response to treatment of breast cancer.

Authors:  J L Berenberg
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.